In ACHIEVE-1 , the first of seven Phase 3 studies in people with type 2 diabetes, orforglipron reduced A1C by an average of 1.3% to 1.6% across doses compared to placebo at 40 weeks, starting from a baseline of 8.0%
Wegovy lawsuits are being pursued for individuals throughout the United States who were hospitalized due to significant gastrointestinal problems or suffered vision problems after using the weight loss drug
I thought to myself, you can either have that, or it can be filled with fat, she quipped
These events are collectively referred to as major adverse cardiovascular events (MACE)
These conditions indicate prior severe acid damage, and any worsening of reflux could accelerate disease progression
The side effect comparison between the two also helps clarify their risk profiles